Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant

By sjmartinez • September 1, 2023

Neven P, Fasching PA, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Zarate JP, Wang Y, Chakravartty A, Wang C, Slamon DJ. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Res. 2023 Aug 31;25(1):103. doi: 10.1186/s13058-023-01701-9. PMID: 37653397; PMCID: PMC10469877.

Tags: Advanced breast cancer, CDK4/6 inhibitor, First line, Hematology/Oncology, overall survival, Publications, ribociclib

Related Posts

ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma

Galanina N, Iqbal M, Tomassetti S, Nousome D, Tin A, Gillespie CP, Youngberg H, Miller P, Malhotra M, Widden H, Rodriguez A, Liu MC, Narkhede[...]

Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1)

Wise-Draper TM, Robert C, Wong MK, Middleton MR, Sacco JJ, In GK, Muñoz Couselo E, Schadendorf D, Beasley GM, Niu J, Chmielowski B, Milhem MM,[...]

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma

Ribas A, Robert C, Schadendorf D, Long GV, Tawbi H, Flaherty K, Ascierto PA, Nathan P, Rutkowski P, Leonov OV, Lorigan P, Prey S, Saponara[...]